A MUC5B PROMOTER POLYMORPHISM AND PULMONARY FIBROSIS IN SSc
Carmel Stock(Guy's and St Thomas' NHS Foundation Trust), Adrian Wells(National Health Service), Hajime Satō(National Institute of Public Health), Toby M. Maher(University of Southern California), CP Denton(The Royal Free Hospital), Dietmar Abraham(Medical University of Vienna), Carla Fonseca, GE Lindahl
UCL Discovery (University College London)
February 1, 2012
Cited by 0
Related Papers
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
|Annals of the Rheumatic Diseases|2003|769
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503
Pulmonary fibrosis secondary to COVID-19: a call to arms?
|The Lancet Respiratory Medicine|2020|498
PD-1 up-regulation on CD4 <sup>+</sup> T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production
|Science Translational Medicine|2018|364
Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study
|The Lancet Respiratory Medicine|2017|299